Back to results
US 11,692,195 B2Granted
Cell-based assay for determining activity in the retinoblastoma pathway
AssigneeMedical Diagnostics Laboratories, LLC
InventorTatyana Naryshkina
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of determining activity of CDK4 and CDK6 variants upon exposure to CDK inhibitors, methods for determining activity of a Rb variant, methods for determining the activity of a p16 variant in a cell, and methods for determining the sensitivity of a CDK4 variant or a CDK6 variant to p16 in a cell. Stable cell lines for determining activity of CDK4 variants, CDK6 variants, Rb variants, and p16 variants are also disclosed.
Claims1
In another aspect, the present invention concerns a cell line comprising:
- a. a first construct comprising a first cDNA encoding E2F1 protein which is linked to Dp-1 protein and a first portion of a luciferase gene at its C-terminus;
- and
- b. a knockout of endogenous CDK4 and endogenous CDK6.
Dependencies are inferred from the claim text.